Bill

Bill > HR8588


US HR8588

US HR8588
Improving the American Drug Supply Chain Act of 2020


summary

Introduced
10/13/2020
In Committee
10/13/2020
Crossed Over
Passed
Dead
12/31/2020

Introduced Session

116th Congress

Bill Summary

Requires the Department of Health and Human Services to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine to (1) study the current and historical production of drugs and key ingredients in the United States and in foreign countries, and (2) formulate recommendations for promoting increased production of drugs and key ingredients in the United States.

AI Summary

This bill requires the Department of Health and Human Services to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine to study the current and historical production of drugs and key ingredients in the United States and foreign countries, and to formulate recommendations for promoting increased domestic production of drugs and key ingredients. The study will evaluate the extent of domestic and foreign drug production, identify the reasons for historical shifts in production locations, and assess the benefits of supply chain redundancies during public health emergencies. The bill also requires the National Academies to consider factors affecting drug production, such as access to labor, costs, taxes, regulations, and the consequences of implementing the recommendations.

Committee Categories

Business and Industry

Sponsors (2)

Last Action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (on 10/13/2020)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...